A PYMNTS Company

US: FTC mounts antitrust probe of Shkreli’s ex-firm Turing

 |  January 24, 2016

The US Federal Trade Commission is investigating Turing Pharmaceuticals for possible antitrust violations in connection with the company’s decision to hike the price of a life-saving drug by more than 5,000 percent, a lawyer for former CEO Martin Shkreli wrote on Friday.

The probe was disclosed in a letter to the US House of Representatives’ Committee on Oversight and Government Reform from Baruch Weiss, Shkreli’s lawyer, as grounds for why his client would not answer questions about drug prices at a Jan. 26 hearing.

The committee had subpoenaed Shkreli, who has been indicted separately on securities fraud charges, to appear to discuss why, as Turing’s CEO, he decided to raise the price of Daraprim to $750 a tablet from $13.50.

The drug, which was acquired by the company, is used to treat toxoplasmosis, a parasitic infection especially dangerous to AIDS patients and others with compromised immune systems.

Full content: NBC News

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.